ArticleBMC pulmonary medicine2026
Relationship of prognostic nutritional index with clinical outcomes and survival in idiopathic pulmonary fibrosis.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease. Nutritional indices have been reported as significant prognostic factors in IPF. This study aimed to evaluate the relationship between the prognostic nutritional index (PNI) and clinical findings, functional parameters, prognosis, and mortality in patients with IPF followed in our clinic.
methodsThis retrospective study reviewed the medical records of patients diagnosed with IPF between 2014 and 2021. The GAP (Gender, Age, Physiology) score, pulmonary function tests, and laboratory results were recorded at the time of diagnosis and at the initiation of antifibrotic treatment. PNI was calculated using serum albumin and lymphocyte counts according to a previously defined formula. Patients were followed from the start of antifibrotic therapy to their final visit within the sixth month. All baseline data were reassessed at the six-month follow-up. Survival time was defined as the period from the initiation of follow-up to the date of death. For patients who were still alive, survival was calculated up to the end of the final data collection, which concluded in December 2024.
resultsA total of 120 patients (86 males; mean age: 69.2 ± 8.5 years) diagnosed with IPF were included. The most common symptoms were dyspnea (87.5%) and cough (82.5%). Forty-eight patients died during the study period. The modified Medical Research Council (mMRC) dyspnea scores and GAP scores were significantly lower in survivors (p = 0.016 and p < 0.001, respectively), whereas PNI levels were significantly higher in this group (p = 0.004). Baseline PNI levels showed weak negative correlations with both the mMRC score (r = - 0.308, p < 0.001) and the GAP score (r = - 0.358, p < 0.001). PNI levels at baseline and at 6 months were significantly higher in patients with stable parenchymal findings than in those with progressive fibrosis (p < 0.001).
conclusionsThese findings suggest that PNI, which reflects both nutritional and inflammatory status, may serve as a useful prognostic marker for predicting disease progression and mortality in patients with IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.